Abstract: A method for reconstituting Sendai viral particles by transfecting Sendai virus to a host expressing all genes for the initial replication has been developed, enabling the Production of negative strand RNA vectors highly useful for practical applications.
Abstract: A method for reconstituting Sendai viral particles by transfecting Sendai virus to a host expressing all genes for the initial replication has been developed, enabling the production of negative strand RNA vectors highly useful for practical applications.
Abstract: Described herein are catechin multimers, and particularly substituted catechin multimers, and their use as carrier moieties for the delivery of nucleophilic and cationic bioactive therapeutic agents to target sites in vivo. For example, substituted catechin multimers of the present invention may be administered alone, for the treatment of stenotic vascular diseases and disorders, such as atherosclerosis (also known as arteriosclerosis) and coronary heart disease (also known as coronary artery disease and ischemic heart disease).
Abstract: A live fish transport system is described herein. In particular, a modular live fish transport tote, an oxygen delivery system, an automated water treatment and delivery apparatus, and a chemically and biologically balanced aquaculture solution are described. Methods of making and using these components, either alone or in combination with each other, are also described.
Abstract: Described herein are novel, therapeutic pharmaceutical and nutraceutical compositions useful for treating stenotic vascular diseases and disorders, such as atherosclerosis and coronary artery disease, and reducing formation of plaque on vascular walls and methods of using same. More particularly, the present invention relates to dietary supplements comprised of gallic acid, or a derivative thereof, in combination with limonene, or a derivative thereof, formulated so as to effectively reduce plaque formation, reversing plaque deposition and degenerative changes in the arterial walls, and/or removal of existing plaques from the vascular walls of animals, preferably humans. The dietary supplements may be formulated “neat” (e.g., without additives) or with additives such as pharmaceutical carriers, diluents, buffers, adjuvants, excipients, surfactants, and stabilizers.
Abstract: Several EHEC proteins which are secreted into the culture supernatant have been discovered. These proteins are not produced by non-pathogenic E. coli, and produce a strong serum antibody response in patients with HUS and bloody diarrhea.
Abstract: The invention described in detail herein relates to the detection, determination, and quantitation of certain ions and small molecules in solution. The invention specifically relates to improvements in the area of photoluminescent sensors for use in a detection scheme involving the alteration of a photoluminescent label or moiety attached to or associated with an analyte binding macromolecule. One may use the changes in photoluminescence lifetime, changes in ratios of photoluminescence intensity or changes in photoluminescence polarization (anisotropy) to determine the analyte. The photoluminescence change measured correlates to the concentration of the ion or molecule in solution.
Type:
Grant
Filed:
March 19, 1999
Date of Patent:
March 6, 2001
Assignee:
University of Maryland, Baltimore
Inventors:
Richard B. Thompson, Vincent L. Feliccia, Badri P. Maliwal, Carol A. Fierke
Abstract: A novel antiproliferative factor (APF) present in urine of patients with interstitial cystitis (IC) is described. This urine antiproliferative factor can serve as a marker for disease activity and its antagonists as therapeutic medicaments for IC. In addition, APF and its agonists can be used for treating diseases associated with cell proliferation.
Type:
Grant
Filed:
October 3, 1997
Date of Patent:
October 5, 1999
Assignee:
University of Maryland
Inventors:
Susan Keay, John W. Warren, Michael Kleinberg, Michael K. Hise